In November, the Centers for Disease Control and Prevention released new guidelines for prescribing opioids for pain, allowing physicians more flexibility. But doctors, patients, and advocates wonder if the updated standards will be too little, too late to help chronic pain patients in a country still focused on fighting the ongoing opioid crisis.
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it’s the arbitrators that jack up prices for those who can least afford them.
The FDA has long blocked the importation of cheap medicine, agreeing with pharmaceutical manufacturers that it opens the door to opioids. The agency’s own data shows that rarely happens.
With Medicare and Social Security apparently off the table for federal budget cuts, the focus has turned to Medicaid, the federal-state health program for those with low incomes. President Joe Biden has made it clear he wants to protect the program, along with the Affordable Care Act, but Republicans will likely propose cuts to both […]
Eli Lilly’s news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.
The billionaire entrepreneur and NBA team owner is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.
The veterinary tranquilizer xylazine, the choice du jour of local drug dealers to cut fentanyl, leads to necrotic ulcers and leaves street medics and physicians confused about how best to deal with this wave of the opioid crisis.
President Joe Biden’s 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of “Medicare for All” maps out his strategy for negotiating with Republicans — and Big Pharma.
This strategy — now in place in at least 10 states — is part of an effort to curb accidental opioid overdose deaths by patients who take these powerful medications.
